Shopping Cart 0
Cart Subtotal
USD 0

China National Pharmaceutical Group Corp-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

China National Pharmaceutical Group Corp (Sinopharm) is a provider of medical and healthcare services. Its core businesses include the distribution, retailing, research and manufacture of healthcare related products. Its product portfolio includes EPI vaccines; biopharmaceutical products; anaesthetics and psychotropics; anti-infective, anti-tumor, cardiovascular and respiratory system drugs; and medicinal herbs. Its business activities include manufacturing and R&D, pharmaceutical logistics and distribution, pharmacy retail chain, anaesthetic distribution, cold-chain distribution for biological products and medical equipment, and distribution of consumable materials, modern and traditional Chinese medicines, besides medical scientific research, engineering design and pharmaceutical international trade. The company has operations across China. Sinopharm is headquartered in Haidian, Beijing, China.

China National Pharmaceutical Group Corp-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10

China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 16

Partnerships 16

Chinese Academy of Engineering Wang Guangji Academic Workstation to Enter into Agreement with Changzhou Fangyuan Pharma and China State Institute of Pharmaceutical Industry 16

Chi-Med Forms Joint Venture with Sinopharm 17

Mitsubishi Forms Joint Venture With Sinopharm 18

China NT Pharma To Form Joint Venture With Sinopharm 18

China State Institute of Pharma Enters Into Research Agreement With Sanofi 19

Aeras Enters Into Co-Development Agreement With China National Biotech Group 20

University of Hong Kong Enters Into Research And Development Agreement With China National Pharma 21

GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 22

Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry 23

Licensing Agreements 23

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 23

Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 24

Pharming Enters Into Licensing Agreement With Shanghai Institute of Pharma Industry 25

Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma 27

Equity Offering 28

Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 28

Sinopharm to Raise USD728 Million in Private Placement of Shares 28

Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 30

Sinopharm Completes Private Placement Of Shares For USD525 Million 30

China National Biotech Plans To Complete IPO For USD1.5 Billion 32

Debt Offering 32

Sinopharm Group Plans Public Offering Of Bonds For USD633 Million 32

China National Biotec Plans Public Offering Of Notes Due 2015 For USD126 Million 33

Sinopharm Group Announces Private Placement Of Medium Term Bonds For USD466 Million 34

Sinopharm Group Completes Private Placement Of Medium Term Bonds For USD308 Million 35

Acquisition 36

Cardinal Health May Sell its Cardinal Health China 36

China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 37

Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 37

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 38

Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For USD49 Million 39

Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.8 Million 40

Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For USD16 Million 41

Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For USD2.8 Million 42

Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 43

Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For USD132.6 Million 43

China National Pharma Acquires 37.1% Stake In Winteam Pharma For USD32.5 Million 44

Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For USD3.3 Million 45

Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For USD6.4 Million 46

China National Accord To Acquire 70% Stake In Guangdong Pharma Company For USD2.14 Million 47

China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For USD5 Million 47

Shanghai Modern Pharma To Acquire 70% Stake In Jiaozuo Rongsheng Pharma For USD33 Million 48

China National Medicines To Acquire 51% Stake In Beijing-Based Medical Company For USD1.4 Million 49

Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 49

China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 50

Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang 51

China National Pharmaceutical Group Corp-Key Competitors 53

Key Employees 54

Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10

China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11


List Of Table

List of Tables

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Key Facts 1

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

China National Pharmaceutical Group Corp, Deals By Therapy Area, 2011 to YTD 2017 10

China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 16

Chinese Academy of Engineering Wang Guangji Academic Workstation to Enter into Agreement with Changzhou Fangyuan Pharma and China State Institute of Pharmaceutical Industry 16

Chi-Med Forms Joint Venture with Sinopharm 17

Mitsubishi Forms Joint Venture With Sinopharm 18

China NT Pharma To Form Joint Venture With Sinopharm 18

China State Institute of Pharma Enters Into Research Agreement With Sanofi 19

Aeras Enters Into Co-Development Agreement With China National Biotech Group 20

University of Hong Kong Enters Into Research And Development Agreement With China National Pharma 21

GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 22

Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry 23

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 23

Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 24

Pharming Enters Into Licensing Agreement With Shanghai Institute of Pharma Industry 25

Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma 27

Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 28

Sinopharm to Raise USD728 Million in Private Placement of Shares 28

Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 30

Sinopharm Completes Private Placement Of Shares For USD525 Million 30

China National Biotech Plans To Complete IPO For USD1.5 Billion 32

Sinopharm Group Plans Public Offering Of Bonds For USD633 Million 32

China National Biotec Plans Public Offering Of Notes Due 2015 For USD126 Million 33

Sinopharm Group Announces Private Placement Of Medium Term Bonds For USD466 Million 34

Sinopharm Group Completes Private Placement Of Medium Term Bonds For USD308 Million 35

Cardinal Health May Sell its Cardinal Health China 36

China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 37

Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 37

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 38

Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For USD49 Million 39

Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.8 Million 40

Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For USD16 Million 41

Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For USD2.8 Million 42

Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 43

Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For USD132.6 Million 43

China National Pharma Acquires 37.1% Stake In Winteam Pharma For USD32.5 Million 44

Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For USD3.3 Million 45

Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For USD6.4 Million 46

China National Accord To Acquire 70% Stake In Guangdong Pharma Company For USD2.14 Million 47

China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For USD5 Million 47

Shanghai Modern Pharma To Acquire 70% Stake In Jiaozuo Rongsheng Pharma For USD33 Million 48

China National Medicines To Acquire 51% Stake In Beijing-Based Medical Company For USD1.4 Million 49

Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 49

China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 50

Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang 51

China National Pharmaceutical Group Corp, Key Competitors 53

China National Pharmaceutical Group Corp, Key Employees 54

China National Pharmaceutical Group Corp, Subsidiaries 55

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

China National Pharmaceutical Group Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

China National Pharmaceutical Group Corp (Sinopharm) is a provider of medical and healthcare services. Its core businesses include the distribution, retailing, research and manufacture of healthcare related products. Its product portfolio includes EPI vaccines; biopharmaceutical products; anaesthetics and psychotropics; anti-infective, anti-tumor, cardiovascular and respiratory system drugs; and medicinal herbs. Its business activities include manufacturing and R&D, pharmaceutical logistics and distribution, pharmacy retail chain, anaesthetic distribution, cold-chain distribution for biological products and medical equipment, and distribution of consumable materials, modern and traditional Chinese medicines, besides medical scientific research, engineering design and pharmaceutical international trade. The company has operations across China. Sinopharm is headquartered in Haidian, Beijing, China.

China National Pharmaceutical Group Corp-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10

China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 16

Partnerships 16

Chinese Academy of Engineering Wang Guangji Academic Workstation to Enter into Agreement with Changzhou Fangyuan Pharma and China State Institute of Pharmaceutical Industry 16

Chi-Med Forms Joint Venture with Sinopharm 17

Mitsubishi Forms Joint Venture With Sinopharm 18

China NT Pharma To Form Joint Venture With Sinopharm 18

China State Institute of Pharma Enters Into Research Agreement With Sanofi 19

Aeras Enters Into Co-Development Agreement With China National Biotech Group 20

University of Hong Kong Enters Into Research And Development Agreement With China National Pharma 21

GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 22

Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry 23

Licensing Agreements 23

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 23

Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 24

Pharming Enters Into Licensing Agreement With Shanghai Institute of Pharma Industry 25

Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma 27

Equity Offering 28

Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 28

Sinopharm to Raise USD728 Million in Private Placement of Shares 28

Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 30

Sinopharm Completes Private Placement Of Shares For USD525 Million 30

China National Biotech Plans To Complete IPO For USD1.5 Billion 32

Debt Offering 32

Sinopharm Group Plans Public Offering Of Bonds For USD633 Million 32

China National Biotec Plans Public Offering Of Notes Due 2015 For USD126 Million 33

Sinopharm Group Announces Private Placement Of Medium Term Bonds For USD466 Million 34

Sinopharm Group Completes Private Placement Of Medium Term Bonds For USD308 Million 35

Acquisition 36

Cardinal Health May Sell its Cardinal Health China 36

China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 37

Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 37

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 38

Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For USD49 Million 39

Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.8 Million 40

Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For USD16 Million 41

Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For USD2.8 Million 42

Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 43

Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For USD132.6 Million 43

China National Pharma Acquires 37.1% Stake In Winteam Pharma For USD32.5 Million 44

Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For USD3.3 Million 45

Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For USD6.4 Million 46

China National Accord To Acquire 70% Stake In Guangdong Pharma Company For USD2.14 Million 47

China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For USD5 Million 47

Shanghai Modern Pharma To Acquire 70% Stake In Jiaozuo Rongsheng Pharma For USD33 Million 48

China National Medicines To Acquire 51% Stake In Beijing-Based Medical Company For USD1.4 Million 49

Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 49

China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 50

Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang 51

China National Pharmaceutical Group Corp-Key Competitors 53

Key Employees 54

Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10

China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11


List Of Table

List of Tables

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Key Facts 1

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

China National Pharmaceutical Group Corp, Deals By Therapy Area, 2011 to YTD 2017 10

China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 16

Chinese Academy of Engineering Wang Guangji Academic Workstation to Enter into Agreement with Changzhou Fangyuan Pharma and China State Institute of Pharmaceutical Industry 16

Chi-Med Forms Joint Venture with Sinopharm 17

Mitsubishi Forms Joint Venture With Sinopharm 18

China NT Pharma To Form Joint Venture With Sinopharm 18

China State Institute of Pharma Enters Into Research Agreement With Sanofi 19

Aeras Enters Into Co-Development Agreement With China National Biotech Group 20

University of Hong Kong Enters Into Research And Development Agreement With China National Pharma 21

GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 22

Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry 23

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 23

Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 24

Pharming Enters Into Licensing Agreement With Shanghai Institute of Pharma Industry 25

Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma 27

Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 28

Sinopharm to Raise USD728 Million in Private Placement of Shares 28

Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 30

Sinopharm Completes Private Placement Of Shares For USD525 Million 30

China National Biotech Plans To Complete IPO For USD1.5 Billion 32

Sinopharm Group Plans Public Offering Of Bonds For USD633 Million 32

China National Biotec Plans Public Offering Of Notes Due 2015 For USD126 Million 33

Sinopharm Group Announces Private Placement Of Medium Term Bonds For USD466 Million 34

Sinopharm Group Completes Private Placement Of Medium Term Bonds For USD308 Million 35

Cardinal Health May Sell its Cardinal Health China 36

China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 37

Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 37

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 38

Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For USD49 Million 39

Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.8 Million 40

Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For USD16 Million 41

Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For USD2.8 Million 42

Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 43

Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For USD132.6 Million 43

China National Pharma Acquires 37.1% Stake In Winteam Pharma For USD32.5 Million 44

Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For USD3.3 Million 45

Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For USD6.4 Million 46

China National Accord To Acquire 70% Stake In Guangdong Pharma Company For USD2.14 Million 47

China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For USD5 Million 47

Shanghai Modern Pharma To Acquire 70% Stake In Jiaozuo Rongsheng Pharma For USD33 Million 48

China National Medicines To Acquire 51% Stake In Beijing-Based Medical Company For USD1.4 Million 49

Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 49

China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 50

Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang 51

China National Pharmaceutical Group Corp, Key Competitors 53

China National Pharmaceutical Group Corp, Key Employees 54

China National Pharmaceutical Group Corp, Subsidiaries 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

China National Pharmaceutical Group Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.